Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis.
Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis.
复制标题
长非编码 RNA HULC 作为人类癌症潜在预后生物标志物：一项荟萃分析
DOI：
10.18632/oncotarget.15247
复制
发表时间：
2017-03-28
期刊：
影响因子：
--
通讯作者：
Zhu XG
中科院分区：
文献类型：
--
作者：
Fan YH;Wu MJ;Jiang Y;Ye M;Lu SG;Wu L;Zhu XG
由于长非编码RNA HULC（肝癌中高度上调）在许多癌症中失调，我们进行了荟萃分析，以确定其在恶性肿瘤中的预后潜力。我们检索了电子数据库，包括PubMed，Medline，奥维德，科克伦图书馆和Web of Science，从开始到2016年8月14日，并确定了7项研究，730例癌症患者进行荟萃分析。我们分析了风险比（HR）和95%置信区间（CI），以确定HULC表达与总生存期（OS）之间的关系。采用RevMan5.3软件计算比值比（OR），分析HULC表达与淋巴结转移（LNM）、远处转移（DM）、肿瘤分期等病理参数的关系。HULC的高表达与OS（HR= 0.50，95%CI：0.35-0.70，P <0.00001）、LNM（OR=0.20，95%CI：0.06-0.64）、DM（OR=0.27，95%CI：0.13-0.54）和肿瘤分期（OR=0.39，95%CI：0.25-0.64）相关。这些荟萃分析数据表明，较高的HULC表达可以是人类癌症中有用的预后生物标志物。
Since the long non-coding RNA HULC (Highly Upregulated in Liver Cancer) is dysregulated in many cancers, we performed a meta-analysis to determine its prognostic potential in malignant tumors. We searched electronic databases, including PubMed, Medline, OVID, Cochrane Library and Web of Science from inception until August 14, 2016 and identified seven studies with 730 cancer patients for the meta-analysis. We analyzed the hazard ratios (HRs) and 95% confidence intervals (CIs) to determine the relationship between HULC expression and overall survival (OS). We also using RevMan5.3 software to calculate odds ratio (ORs) to assess the association between HULC expression and pathological parameters, including lymph node metastasis (LNM), distant metastasis (DM) and the tumor stage. Our analysis showed that higher HULC expression was associated with OS (HR= 0.50, 95% CI: 0.35–0.70, P <0.00001), LNM (OR=0.20, 95 % CI 0.06–0.64), DM (OR=0.27, 95% CI: 0.13–0.54) and the tumor stage (OR=0.39, 95 % CI 0.25–0.64). These meta-analysis data demonstrate that higher HULC expression can be a useful prognostic biomarker in human cancers.